Aggiudicatario

Novartis Gene Therapies EU Ltd.

Dublin 9 · IRL

Segui questa schedaCon Adjudera Pro ricevi un avviso prima che un contratto qui scada.

Aggiudicazioni

Importo totale aggiudicato

—

0 / 9 con importo

Stazioni appaltanti

Settori

Reg. [Novartis Gene Therapies EU Ltd.]

Contratti di questo aggiudicatario in scadenza

31 dic 2026
dichiarata
Onasemnogen abeparvovec 166.00 Mrd., Onasemnogen abeparvovec 110.00 Mrd. in 5.5 ml Lsg. 8.3 ml Lsg. Infusionslösung St a 22.0 ml
PBMG eGNovartis Gene Therapies EU Ltd.
—
31 dic 2026
dichiarata
Onasemnogen abeparvovec 166.00 Mrd., Onasemnogen abeparvovec 110.00 Mrd. in 5.5 ml Lsg. 8.3 ml Lsg. Infusionslösung St a 27.5 ml
PBMG eGNovartis Gene Therapies EU Ltd.
—
31 dic 2026
dichiarata
Onasemnogen abeparvovec 166.00 Mrd., Onasemnogen abeparvovec 110.00 Mrd. in 5.5 ml Lsg. 8.3 ml Lsg. Infusionslösung St a 30.3 ml
PBMG eGNovartis Gene Therapies EU Ltd.
—
31 dic 2026
dichiarata
Onasemnogen abeparvovec 166.00 Mrd., Onasemnogen abeparvovec 110.00 Mrd. in 5.5 ml Lsg. 8.3 ml Lsg. Infusionslösung St a 33.0 ml
PBMG eGNovartis Gene Therapies EU Ltd.
—
31 dic 2026
dichiarata
Onasemnogen abeparvovec 166.00 Mrd., Onasemnogen abeparvovec 110.00 Mrd. in 5.5 ml Lsg. 8.3 ml Lsg. Infusionslösung St a 35.8 ml
PBMG eGNovartis Gene Therapies EU Ltd.
—
31 dic 2026
dichiarata
Onasemnogen abeparvovec 166.00 Mrd., Onasemnogen abeparvovec 110.00 Mrd. in 5.5 ml Lsg. 8.3 ml Lsg. Infusionslösung St a 38.5 ml
PBMG eGNovartis Gene Therapies EU Ltd.
—
31 dic 2026
dichiarata
Onasemnogen abeparvovec 166.00 Mrd., Onasemnogen abeparvovec 110.00 Mrd. in 5.5 ml Lsg. 8.3 ml Lsg. Infusionslösung St a 52.3 ml
PBMG eGNovartis Gene Therapies EU Ltd.
—
31 dic 2026
dichiarata
Onasemnogen abeparvovec 166.00 Mrd., Onasemnogen abeparvovec 110.00 Mrd. in 5.5 ml Lsg. 8.3 ml Lsg. Infusionslösung St a 55.0 ml
PBMG eGNovartis Gene Therapies EU Ltd.
—
31 dic 2026
dichiarata
Onasemnogen abeparvovec 166.00 Mrd., Onasemnogen abeparvovec 110.00 Mrd. in 5.5 ml Lsg. 8.3 ml Lsg. Infusionslösung St a 60.5 ml
PBMG eGNovartis Gene Therapies EU Ltd.
—

Tutti i contratti in scadenza →

Aggiudicazioni

Aggiudicazione	Stazione appaltante	Aggiudicatario	Importo dell’appalto	Pubblicato
Onasemnogen abeparvovec 166.00 Mrd., Onasemnogen abeparvovec 110.00 Mrd. in 5.5 ml Lsg. 8.3 ml Lsg. Infusionslösung St a 60.5 ml	PBMG eG	Novartis Gene Therapies EU Ltd.	—	2 mar 2026
Onasemnogen abeparvovec 166.00 Mrd., Onasemnogen abeparvovec 110.00 Mrd. in 5.5 ml Lsg. 8.3 ml Lsg. Infusionslösung St a 55.0 ml	PBMG eG	Novartis Gene Therapies EU Ltd.	—	2 mar 2026
Onasemnogen abeparvovec 166.00 Mrd., Onasemnogen abeparvovec 110.00 Mrd. in 5.5 ml Lsg. 8.3 ml Lsg. Infusionslösung St a 52.3 ml	PBMG eG	Novartis Gene Therapies EU Ltd.	—	2 mar 2026
Onasemnogen abeparvovec 166.00 Mrd., Onasemnogen abeparvovec 110.00 Mrd. in 5.5 ml Lsg. 8.3 ml Lsg. Infusionslösung St a 38.5 ml	PBMG eG	Novartis Gene Therapies EU Ltd.	—	2 mar 2026
Onasemnogen abeparvovec 166.00 Mrd., Onasemnogen abeparvovec 110.00 Mrd. in 5.5 ml Lsg. 8.3 ml Lsg. Infusionslösung St a 35.8 ml	PBMG eG	Novartis Gene Therapies EU Ltd.	—	2 mar 2026
Onasemnogen abeparvovec 166.00 Mrd., Onasemnogen abeparvovec 110.00 Mrd. in 5.5 ml Lsg. 8.3 ml Lsg. Infusionslösung St a 33.0 ml	PBMG eG	Novartis Gene Therapies EU Ltd.	—	2 mar 2026
Onasemnogen abeparvovec 166.00 Mrd., Onasemnogen abeparvovec 110.00 Mrd. in 5.5 ml Lsg. 8.3 ml Lsg. Infusionslösung St a 30.3 ml	PBMG eG	Novartis Gene Therapies EU Ltd.	—	2 mar 2026
Onasemnogen abeparvovec 166.00 Mrd., Onasemnogen abeparvovec 110.00 Mrd. in 5.5 ml Lsg. 8.3 ml Lsg. Infusionslösung St a 27.5 ml	PBMG eG	Novartis Gene Therapies EU Ltd.	—	2 mar 2026
Onasemnogen abeparvovec 166.00 Mrd., Onasemnogen abeparvovec 110.00 Mrd. in 5.5 ml Lsg. 8.3 ml Lsg. Infusionslösung St a 22.0 ml	PBMG eG	Novartis Gene Therapies EU Ltd.	—	2 mar 2026